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INTRODUCTION: Testosterone is needed for normal male development, muscle strength, bone mineralization, hematopoietic 
function, and sexual and reproductive functions. The main purpose of androgen deprivation therapy in prostate cancer is to reduce 
tumor progression, but therapy is often accompanied by significant adverse effects.
OBJECTIVE: This study aimed to determine the effects of androgen deprivation therapy on body composition and resting meta-
bolic rate in patients with prostate cancer.
PATIENTS AND METHODS: A prospective study was performed to evaluate the body composition of 16 elderly males (aged 
63-96; median age 71) with prostate cancer scheduled for orchiectomy, one year before and after surgery. Body composition was 
measured by DEXA, and energy expenditure, fat and carbohydrate oxidation were measured by indirect calorimetry.
RESULTS: Body weight (p=0.01), lean mass (p=0.004), and lipid oxidation (p=0.001) decreased significantly. Carbohydrate oxida-
tion (p=0.02), FSH (p=0.0001) and LH (p=0.0001) levels increased significantly. Changes in fat mass (p=0.06) and bone mineral 
density (p=0.48) were not significant. 
CONCLUSIONS: After 12 months of androgen deprivation therapy, elderly men with metastatic prostate cancer exhibit a decline 
in lean body mass and lipid oxidation, together with increased carbohydrate oxidation.
KEYWORDS: Androgen deprivation; Metastatic prostate cancer; Hormonotherapy side effects; Lean body mass; Lipolysis regu-
lation.
INTRODUCTION
The prostate is the site of two common diseases in aging 
men, benign prostatic hyperplasia and prostate cancer (PCa). 
Epidemiological studies show that, in the United States, PCa 
accounts for 28.7% of new non-skin cancers and 12.7% 
of cancer-related deaths.1 Androgen deprivation therapy 
(ADT) retards PCa progression in 60%–80% of patients 
but may cause cardiovascular complications and alterations 
in body composition, lipoprotein metabolism, and sexual 
function. In general, ADT may result in a decreased quality 
of life. Furthermore, studies in men demonstrate that low 
serum testosterone (T) levels are associated with several 
cardiovascular risk factors,2,3 such as lower high density 
lipoprotein cholesterol, higher triglyceride concentrations, 
hyperinsulinemia, and increased abdominal adiposity. 
These factors are all characteristic of the metabolic insulin 
resistance syndrome. In addition, many patients treated with 
ADT experience rapid bone loss that increases the risk of 
debilitating osteoporotic fractures.4-6 Reports indicate that 
total and free levels of serum T decline in aging men and that 
abdominal visceral fat is inversely associated with T levels. 
Resting energy expenditure (REE), which accounts for 
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60%–70% of total daily energy expenditure, decreases with 
age, physical inactivity, sympathetic nervous system and 
endocrine status.7,8 To our knowledge, the effects of ADT on 
REE have not been fully explored in controlled trials. The 
goal of this prospective study was to determine the effects 
of ADT on body composition and resting metabolic rate in 
patients with metastatic PCa. 
PATIENTS AND METHODS
Sixteen men, aged 63 to 96 years (mean age 71), with 
untreated metastatic PCa were enrolled in this study.
Prior to orchiectomy, all patients were evaluated 
clinically and by laboratory analysis to establish a baseline. 
After a careful medical history had been taken from each 
patient, we assessed several exclusion criteria, namely, 
cognitive alterations, depression and emotional liability.
Laboratory examinations included tests of FSH-LH 
serum concentrations, and an evaluation of body mass index, 
fat/lean body mass, bone mineral density, carbohydrate/lipid 
oxidation, and resting energy expenditure.
Following orchiectomy, the same evaluation was carried 
out monthly and after 12 months, the period chosen for final 
analysis.
To evaluate body composition, all patients underwent 
densitometry testing (dual-energy X ray absorptiometry - 
DEXA).9 The REE, fat and carbohydrate oxidation levels 
were measured using indirect calorimetry, with a Delta-
TRAC Metabolic Monitor.10 Body composition analyses and 
indirect calorimetry were carried out at baseline and after 12 
months following the orchiectomy procedure. 
Written consent was obtained from all patients, and 
this protocol was approved by the Ethics Committee at our 
institution.
Statistical analysis
We used the non-parametric two-sided Wilcoxon t-test, 
and p<0.05 was considered significant to appropriately 
compare time differences for each variable.11
RESULTS
Statistically significant differences in body composition 
pre and post orchiectomy were seen in terms of weight, 
body mass index (BMI) and lean body mass (LBM). Total 
fat body mass (FBM) exhibited a tendency to increase but 
failed to reach significance. No significant changes were 
observed in bone mineral density (BMD) and REE, but 
we identified a statistically significant change in terms of 
increased carbohydrate oxidation (CHOox) and a decrease in 
lipid oxidation (LIPIDox). These results are listed in Table 1.
DISCUSSION
Aging is associated with sarcopenia (loss of muscle 
mass), with an average 12 kg loss of LBM between the ages 
of 25 and 70 years and an increase in FBM of 18%–36% 
during the same period.2 Testosterone levels exhibit a 
positive correlation with LBM and a negative correlation 
with FBM. This has led to the hypothesis that ADT may help 
mitigate age-related alterations in body composition.
Our study reports two major findings: 1) ADT was 
associated with decreased body weight and with decreased 
LBM; 2) ADT led to increased CHOox and decreased 
LIPIDox. 
Androgens modulate body composition, including lipid 
and protein metabolism.12 Smith et al,13 Galvão et al,14 
Levy et al,15 and Van Londen et al16 observed significant 
Table 1 - Mean values of variables at baseline and 12 months after orchiectomy 
Variables Basal (mean ± SD) 12 months (mean ± SD) Δ % (mean ± SD) p
Weight (kg) 72.5 ± 11.6 70.2 ± 11.5 -3.4 ± 1.3 0.01
Body mass index (kg/m2) 26.0 ± 3.6 25.1 ± 3.8 -3.0 ± 1.4 0.02
Fat body mass (kg) 27.5 ± 10.9 34.7 ± 14.9 36.0 ± 15.1 0.06
Lean body mass (kg) 39.8 ± 9.5 28.0 ± 14.3 -30.2 ± 8.0 0.004
Bone mineral density (g/cm2) 1.990 ± 0.461 1.997 ± 0.432 2.0 ± 4.7 0.48
Carbohydrate oxidation (mg/min) 56.7 ± 20.7 70.1 ± 14.7 52.6 ± 28.0 0.02
Lipid oxidation (mg/min) 43.2 ± 20.6 30.3 ± 14.0 -4.1 ± 26.9 0.01
Resting energy expenditure (kcal/24h) 1.177 ± 237.7 1.072 ± 323.5 -7.1 ± 7.3 0.26
LH (IU/L) 12.4 ± 3.3 54.5 ± 6.7 735 ± 17.7 0.0001
FSH (IU/L) 6.9 ± 1.6 34.8 ± 4.4 990 ± 302.5 0.0001
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changes in metabolic and body composition parameters 
after 6 months of induced hypogonadism in all patients. 
These studies included 22, 72, 35 and 81 men, respectively. 
The researchers observed a significant increase in FBM 
(20.2±9.4 to 21.9±9.6 kg,13 13.8±2.3%,14 1.17±2.3 %,15 
and 2167.15 g,16 respectively) and a significant decrease 
in LBM (63.2±8.0 to 62.3±5.4 Kg,13 –2.4 ± 0.4%,14 
–1.15±2.20%;15 and –1785.81 g,16 respectively) with no 
significant changes in total body weight, lipid readings or 
glucose metabolism. 
They also reported a positive correlation between 
the changes in FBM and insulin concentrations (r=0.56; 
p=0.013). These results are in agreement with other 
studies that demonstrated a relationship between T and 
abnormalities in carbohydrate and lipid metabolism.17
In healthy male populations, low T concentrations are 
negatively correlated with the degree of central abdominal 
obesity. In hypogonadal males, there is a tendency toward 
increased visceral adiposity and reduced muscle mass that 
can be reversed by androgen replacement.18 The underlying 
mechanisms for these observations are not well defined, 
but androgen receptors are known to be present on visceral 
adipocytes. It is likely that T is directly involved in the 
mobilization of free fatty acids.19
We observed significant changes in metabolic and 
body composition in our patients after ADT. We identified 
significant decreases in total body weight, BMI and LBM 
(2.5 kg, p = 0.01; -0.8 kg/cm², p = 0.02, -11.7 kg, p = 0.002, 
respectively). FBM was found to increase (7.15 kg, p = 
0.06) with no significant change in bone mineral density 
(BMG). There were no changes in REE, but we did identify 
a significant increase in CHOox and a decrease in LIPIDox 
(52.62%, -4.10% respectively). In one study, suppression 
of T levels after 10 weeks of GnRH agonist administration 
was found to reduce REE in young men. In this study, 
researchers were unable to determine whether the effect was 
directly mediated by a reduction in T levels or if it was due 
to a subsequent reduction in T aromatization to estrogen.20 
We were unable to show alterations in REE in our study, 
possibly due to the size of our study sample. The altered 
concentrations of gonadotropins following orchiectomy may 
be linked with the effects of this procedure on the pituitary 
gland. It is possible that other pituitary hormones (growth 
hormone) are also affected. This in turn may contribute to 
the observed changes in body composition. It is important 
to consider that ADT not only acts on PCa but also affects 
metabolism, including hematogenesis, bone, fat, protein, and 
sarcho-metabolism. Despite PCa being one of the leading 
causes of death, a substantial proportion of aging patients 
die of unrelated causes that are due to comorbidities, often 
in the context of metabolic syndrome.
The present study has several strengths and some 
limitations. To our knowledge, this is the first prospective 
study to examine changes in body composition, resting 
energy expenditure, and consequences involving the 
oxidation of carbohydrates and lipids in the context of ADT. 
A study on a larger group of patients would be of great 
interest once a limited number of patients included from 
only one centre may be considered a limitation in this study.
CONCLUSION 
After 12 months of androgen deprivation therapy, elderly 
males with metastatic prostate cancer exhibit declines in lean 
body mass and lipid oxidation, together with an increase in 
carbohydrate oxidation. 
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